Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CollPlant Biotechnologies (CLGN) Change in Receivables (2018 - 2025)

Historic Change in Receivables for CollPlant Biotechnologies (CLGN) over the last 8 years, with Q3 2025 value amounting to -$11000.0.

  • CollPlant Biotechnologies' Change in Receivables fell 10448.98% to -$11000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6000.0, marking a year-over-year decrease of 50000.0%. This contributed to the annual value of -$150000.0 for FY2024, which is 176666.67% down from last year.
  • Per CollPlant Biotechnologies' latest filing, its Change in Receivables stood at -$11000.0 for Q3 2025, which was down 10448.98% from $150000.0 recorded in Q1 2025.
  • CollPlant Biotechnologies' 5-year Change in Receivables high stood at $10.2 million for Q3 2023, and its period low was -$9.8 million during Q2 2023.
  • Its 5-year average for Change in Receivables is $104411.8, with a median of $4000.0 in 2023.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 30564.26% in 2021, then plummeted by 10920000.0% in 2023.
  • Quarter analysis of 5 years shows CollPlant Biotechnologies' Change in Receivables stood at $560000.0 in 2021, then tumbled by 53.39% to $261000.0 in 2022, then plummeted by 98.47% to $4000.0 in 2023, then plummeted by 3725.0% to -$145000.0 in 2024, then skyrocketed by 92.41% to -$11000.0 in 2025.
  • Its Change in Receivables was -$11000.0 in Q3 2025, compared to $150000.0 in Q1 2025 and -$145000.0 in Q4 2024.